147 related articles for article (PubMed ID: 9537586)
1. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
Helfrich W; Kroesen BJ; Roovers RC; Westers L; Molema G; Hoogenboom HR; de Leij L
Int J Cancer; 1998 Apr; 76(2):232-9. PubMed ID: 9537586
[TBL] [Abstract][Full Text] [Related]
2. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
4. High level secretion of a humanized bispecific diabody from Escherichia coli.
Zhu Z; Zapata G; Shalaby R; Snedecor B; Chen H; Carter P
Biotechnology (N Y); 1996 Feb; 14(2):192-6. PubMed ID: 9636323
[TBL] [Abstract][Full Text] [Related]
5. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
Kipriyanov SM; Moldenhauer G; Strauss G; Little M
Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
[TBL] [Abstract][Full Text] [Related]
6. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
Zhu Z; Lewis GD; Carter P
Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
[TBL] [Abstract][Full Text] [Related]
7. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
8. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
9. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
10. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
[TBL] [Abstract][Full Text] [Related]
11. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
[TBL] [Abstract][Full Text] [Related]
12. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
[TBL] [Abstract][Full Text] [Related]
13. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
14. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
15. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
17. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
18. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
19. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.
Holliger P; Brissinck J; Williams RL; Thielemans K; Winter G
Protein Eng; 1996 Mar; 9(3):299-305. PubMed ID: 8736497
[TBL] [Abstract][Full Text] [Related]
20. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]